Maybe, maybe not. Every stock has a tipping point. This news is going to be reverberating throughout the US now. There is significant interest from CAR T players currently only able to treat blood cancers. This is a lucrative space and Imugene is attaining credibility at the forefront of this market segment. I bet Estrellas gains traction in the US after this presentation...
